ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
ImmunityBio, Inc. (NASDAQ:IBRX) has received a "Moderate Buy" consensus rating from analysts, with six out of seven brokerages recommending a buy. The average 12-month price target is $14.20, significantly higher than the current share price of $7.72. Despite quarterly earnings missing analyst expectations, the company's revenue exceeded estimates, and institutional investors have been increasing their holdings.
Patrick Soon-Shiong to Thomas Ichim: Thanks for Sharing Important Difference Between Il-2 and Il-15
Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, acknowledged a post by Thomas Ichim, President and Chief Scientific Officer at Immorta Bio, highlighting the critical difference between IL-2 and IL-15 in cancer immunotherapy. Soon-Shiong emphasized that IL-2 stimulates suppressor cells while IL-15 activates killer cells, suggesting that past immunotherapy development may have focused on the wrong cytokine. This interaction underscores the importance of a paper titled "Advances in IL–15–Based Cancer Immunotherapy and Divergent Immunological Effects of IL–2 and IL–15 Signaling via the Shared IL–2Rβγ Receptor."
ImmunityBio (IBRX) Shares Moved, What Is Behind The Fresh Attention?
ImmunityBio (IBRX) has garnered renewed attention after appointing Dr. Jim Yong Kim as Vice Chairman, signaling a focus on expanding global partnerships and access to its immunotherapy programs. Despite a significant year-to-date share price increase of 292.08%, the company's valuation narrative suggests it is 39.1% undervalued, with a fair value of $13 per share based on projected global expansion of ANKTIVA. However, the article cautions that this potential is contingent on successful trial outcomes and regulatory approvals.
ImmunityBio (IBRX) Shares Moved, What Is Behind The Fresh Attention?
ImmunityBio (IBRX) is gaining attention due to the appointment of Dr. Jim Yong Kim as Vice Chairman, aimed at enhancing global partnerships and access to its immunotherapy programs. The stock has seen significant price increases, with a 292.08% year-to-date return, and a narrative suggests it is 39.1% undervalued with a fair value of $13 per share based on the global expansion of ANKTIVA. Investors are advised to consider both opportunities and risks, such as potential trial failures or regulatory challenges.
147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.
Hussman Strategic Advisors Inc. acquired 147,000 shares of ImmunityBio, Inc. (IBRX) during the second quarter, valued at approximately $1.29 million. Institutional investors now hold 8.58% of the company, while corporate insiders own 66.10%, despite recent insider selling totaling about $3.92 million. ImmunityBio reported a Q2 loss of $0.22 per share but exceeded revenue estimates with $51.24 million, and analysts currently rate the stock as a "Moderate Buy" with an average price target of $14.20.
Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)?
ImmunityBio (IBRX) recently appointed former World Bank president Dr. Jim Yong Kim as Vice Chairman to focus on global strategy and international access to its therapies. This move signals ImmunityBio's intent to engage more deeply with governments and public health agencies, influencing how its treatments are introduced and accessed globally. While Dr. Kim's expertise could bolster long-term international growth, the company still faces significant near-term challenges including heavy cash burn and deepening losses despite growing sales.
Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)?
ImmunityBio recently appointed former World Bank president Dr. Jim Yong Kim as Vice Chairman to lead global strategy and international access for its immunotherapy platform. This move signals ImmunityBio's intention to engage more deeply with governments and public health agencies worldwide, impacting how its therapies will be introduced and accessed internationally. While this suggests a focus on long-term global expansion, it occurs amidst growing sales but also deepening financial losses, highlighting a tension between ambitious growth and financial strain.
Jim Yong Kim Joins ImmunityBio as Vice Chairman
ImmunityBio has appointed Jim Yong Kim, former President of the World Bank Group, as its Vice Chairman. In this new role, Kim will focus on strengthening the company's international relationships and supporting global partnerships and access initiatives for its immunotherapy platforms, clinical programs, and approved therapies. His extensive background in global health and development finance is expected to aid ImmunityBio's mission to make scientific and medical advancements accessible to those most in need.
IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough
ImmunityBio (IBRX) stock saw a jump after executive chairman Patrick Soon-Shiong revealed a three-year expansion plan for the BioShield platform, which includes Anktiva. The company is expanding Anktiva's reach globally, notably into Saudi Arabia and across Europe, following recent regulatory approvals. Soon-Shiong also highlighted the potential of Anktiva's IL-15 mechanism in cancer immunotherapy and outlined plans for a "world bank of natural killer cells" using AI-driven manufacturing.
Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus
This article highlights several technology and growth companies, including Archer Aviation (ACHR), ImmunityBio (IBRX), Sphere 3D Corp. (ANY), Graphene Manufacturing Group (GMG), and Socket Mobile (SCKT), which are attracting investor attention due to recent corporate, technology, and strategic developments. Archer Aviation is expanding its position in advanced air mobility, ImmunityBio appointed a new Vice Chairman to its board, Sphere 3D Corp. is repositioning around digital infrastructure and AI, Graphene Manufacturing Group is revitalizing its battery brand, and Socket Mobile announced a strategic partnership for its mobility solutions. These companies represent key investment themes such as eVTOL, biotechnology, AI/HPC infrastructure, advanced batteries, and enterprise mobility.
Jim Yong Kim Joins ImmunityBio as Vice Chairman – ImmunityBio
ImmunityBio announced that Dr. Jim Yong Kim, former President of the World Bank Group, has joined the company as Vice Chairman. He will be part of the newly formed Office of the Executive Chairman and will focus on strengthening ImmunityBio's international and global relationships. His extensive experience in medicine, public health, and development is expected to be crucial in the company's mission to deliver immune activation benefits to patients globally.
ImmunityBio Names Former World Bank President Jim Yong Kim Vice Chairman
ImmunityBio, Inc. (NASDAQ: IBRX) has appointed former World Bank President Dr. Jim Yong Kim as vice chairman to strengthen international partnerships for its immunotherapy programs and approved therapies. Kim will focus on building relationships with governments, health ministries, and multilateral organizations to expand global access to ImmunityBio's treatments. His extensive experience in global health and development finance is expected to be invaluable as the company navigates international commercialization and healthcare systems.
ImmunityBio appoints Jim Yong Kim as vice chairman
ImmunityBio, Inc. (NASDAQ:IBRX) has announced the appointment of Dr. Jim Yong Kim as vice chairman, who will focus on international partnerships and global access initiatives within the newly created Office of the Executive Chairman. Dr. Kim, a former president of the World Bank Group and co-founder of Partners In Health, will leverage his extensive experience in global health to support the company's immunotherapy platform and therapies outside the United States. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong.
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
ImmunityBio, Inc. (NASDAQ: IBRX) has appointed Dr. Jim Yong Kim, former World Bank President, as Vice Chairman to lead international partnerships and global access initiatives. Dr. Kim will work within a newly formed Office of the Executive Chairman, reporting to Dr. Patrick Soon-Shiong, to expand global access to ImmunityBio's immunotherapy platform and approved therapies. His extensive background in global health, development finance, and government relations is expected to accelerate the company's scientific and clinical programs worldwide.
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
ImmunityBio, Inc. has appointed Dr. Jim Yong Kim, former World Bank President and global health leader, as Vice Chairman. In this newly created role within the Office of the Executive Chairman, Dr. Kim will focus on strengthening international relationships, engaging with governments and health ministries, and supporting global access initiatives for ImmunityBio's immunotherapy platform. His extensive experience in medicine, public health, and global finance is expected to be invaluable in advancing the company's scientific programs and expanding access to its therapies worldwide.
Royal Bank of Canada Has $11.40 Million Holdings in ImmunityBio, Inc. $IBRX
Royal Bank of Canada significantly increased its stake in ImmunityBio, Inc. (NASDAQ:IBRX) by 1,731.8% in the first quarter, now holding 1.4 million shares valued at $11.4 million. Despite the company reporting a larger-than-expected quarterly loss of $0.22 per share, institutional ownership remains at 8.58% and analysts have a "Moderate Buy" consensus rating with an average price target of $14.20. Recent insider transactions show sales by two directors, though company insiders still own 66.10% of the stock.
ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach
ImmunityBio (IBRX) is under investor scrutiny after receiving marketing authorization in the UAE for ANKTIVA, used for bladder cancer and lung cancer. While the stock has seen significant year-to-date gains, its current valuation reflects rich revenue multiples and ongoing losses. Analysts present mixed views, with some seeing the company as undervalued with a fair value of $13, driven by aggressive growth forecasts, while others point to high sales multiples and remaining risks.
Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next
ImmunityBio (IBRX) saw its stock rise by 6.6% following its Q2 2026 results and the expanded UAE marketing authorization for its immunotherapy ANKTIVA, now covering bladder and lung cancer in 34 countries. Despite increased revenue, the company reported wider net losses, highlighting the challenge of balancing commercial expansion with significant ongoing losses. The article emphasizes that while regulatory approvals are positive, the company's investment narrative remains centered on ANKTIVA's ability to evolve into a broader oncology platform amidst continued substantial losses.
Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next
ImmunityBio (IBRX) saw its stock rise by 6.6% following its Q2 2026 results, which showed increased revenue but also a wider net loss. The company also secured broad UAE marketing authorization for its immunotherapy ANKTIVA for bladder and lung cancer, expanding its global regulatory footprint to 34 countries. This development highlights the company's growing commercial reach despite significant ongoing losses, and future expectations will hinge on ANKTIVA's broader oncology platform development and further regulatory progress.
ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value
ImmunityBio (IBRX) has shown strong stock performance with a 321.9% gain over three years, driven by recent approvals for ANKTIVA. However, the stock appears overvalued based on its current Price-to-Sales (P/S) ratio of 46.8x, significantly higher than the biotech industry average. While there is optimism around future growth and revenue potential, the current valuation implies high expectations, leaving limited room for disappointment.
ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake
ImmunityBio, Inc. (IBRX) is majority-controlled by Patrick Soon-Shiong and affiliated entities, who beneficially own 64.8% of the common stock, totaling 745,518,285 shares. This ownership is distributed among several entities, including Cambridge Equities, Nant Capital, California Capital Equity, and NantWorks. The report is based on an SEC SCHEDULE 13D/A filing, highlighting the significant influence of Dr. Soon-Shiong over the company.
Immunitybio Inc earnings missed by $0.14, revenue topped estimates
Immunitybio Inc (NASDAQ: IBRX) reported second-quarter earnings per share of $-0.22, missing analyst estimates by $0.14. However, the company's revenue for the quarter was $51.24 million, surpassing the consensus estimate of $47.22 million. The stock is down 7.86% in the last three months but up 196.68% over the last year.
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
ImmunityBio, Inc. announced record net product revenue of $50.7 million for Q2 2026, marking a 92% increase year-over-year and its eighth consecutive quarter of sequential growth. First-half revenue for 2026 reached $94.8 million, up 121% from 2025, driven by strong adoption of ANKTIVA. The company also reported over $350 million in cash and cash equivalents, and marketable securities, supporting its continued advancements in clinical programs and global expansion of ANKTIVA.
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
ImmunityBio (IBRX) reported a Q2 loss of $0.08 per share, surpassing the Zacks Consensus Estimate of a $0.09 loss and showing an 11.11% earnings surprise. The company also beat revenue estimates, posting $51.24 million against an estimated $48.45 million. ImmunityBio's stock has seen a significant 261.1% gain year-to-date, outperforming the S&P 500.
Immunitybio Inc earnings missed by $0.14, revenue topped estimates
Immunitybio Inc (NASDAQ: IBRX) reported second-quarter EPS of $-0.22, missing analyst estimates by $0.14. However, the company's revenue of $51.24M surpassed the consensus estimate of $47.22M. The stock has seen a significant increase of 196.68% over the last 12 months, despite a recent 7.86% decline in the last three months.
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales
ImmunityBio (IBRX) reported record second-quarter revenue of $51.2 million, surpassing Wall Street estimates, largely driven by strong sales of its cancer therapy, Anktiva. Despite a wider net loss due to non-cash accounting charges, Chairman Patrick Soon-Shiong highlighted the company's focus on expanding Anktiva's applications and accelerating its international rollout, including recent approval in the UAE. Retail sentiment remains bullish, with the stock having surged nearly 254% year-to-date.
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
ImmunityBio (NASDAQ: IBRX) announced record Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase, driven by the continued adoption of ANKTIVA. First-half 2026 revenue also saw significant growth, reaching $94.8 million, up 121% from the previous year. The company highlighted advancements in its clinical pipeline, regulatory approvals for ANKTIVA in new markets, and a strong cash position of over $350 million.
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors who purchased securities prior to January 19, 2026, and continue to hold them. The investigation focuses on possible corporate wrongdoing by ImmunityBio and its officers/directors. The firm operates on a contingency fee basis, seeking to recover investor capital and ensure corporate accountability.
ImmunityBio Releases Q2 2026 Financial Results
ImmunityBio, Inc. (IBRX) reported a net loss of $230.4M and a loss per share of $0.22 for Q2 2026, widening from Q2 2025 as the company invests in its immunotherapy platform. Despite increased losses, revenue grew significantly to $51.2M, up 92.0% year-over-year, driven by strong ANKTIVA net product revenue of $50.7M. Analysts maintain an optimistic outlook with a consensus of 5 buy ratings.
Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M
ImmunityBio, Inc. (IBRX) reported Q2 revenue of $51.2 million, surpassing the FactSet estimate of $49.7 million. This earnings flash indicates stronger-than-expected revenue performance for the biotechnology company in the second quarter.
ImmunityBio, Inc. (IBRX) Q2 2026 Earnings
ImmunityBio, Inc. (IBRX) reported its Q2 2026 earnings, with an EPS of -$0.22 against an estimated -$0.08, and revenue of $51M, exceeding the $50M estimate. The company's ANKTIVA revenue saw a 94% year-over-year increase, marking its eighth consecutive quarter of sequential gains. The EPS miss was attributed to non-cash charges related to warrant and derivative fair value, while an FDA decision on a broader bladder cancer label is anticipated by January 6, 2027.
ImmunityBio Q2 revenue rises 92% to record $50.7 million
ImmunityBio (IBRX) reported a significant increase in Q2 2026 total revenue, reaching $51.2 million, with net product revenue up 92% year-over-year to a record $50.7 million. The company's ANKTIVA product continues to drive growth, marking its eighth consecutive quarter of sequential revenue increase, and has received expanded regulatory approvals. Despite the revenue growth, ImmunityBio reported a net loss of $230.4 million, while insiders have primarily engaged in sales of IBRX stock, and hedge funds show mixed activity with some significantly increasing and others decreasing their holdings.
Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX)
ImmunityBio (NASDAQ: IBRX) reported record Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase, and $94.8 million for the first half of 2026. Despite this revenue growth, the company experienced a higher GAAP net loss of $230.4 million in Q2 and $863.2 million for the first half, primarily due to non-cash fair value changes of warrant and derivative liabilities. The company maintained a strong cash position of $357.4 million and advanced its ANKTIVA program with new marketing authorizations and regulatory milestones.
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. (NASDAQ:IBRX) securities who bought shares prior to January 19, 2026, and continue to hold them. The investigation aims to determine if ImmunityBio and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them for additional information and to assist in the investigation without any upfront cost, as they operate on a contingency fee basis.
ImmunityBio (IBRX) Could Be 45% Undervalued On UAE ANKTIVA Approval
ImmunityBio (IBRX) has received marketing authorization for ANKTIVA in the UAE for two cancer indications, expanding its global footprint. Despite a recent share price pullback, the company is considered 45% undervalued by the most followed narrative, with a fair value of $13 per share. This approval strengthens the growth story around ANKTIVA's rapid global expansion, although investors are advised to consider risks such as ImmunityBio's net loss and potential regulatory setbacks.
ImmunityBio (IBRX) Could Be 45% Undervalued On UAE ANKTIVA Approval
ImmunityBio (IBRX) has received marketing authorization for ANKTIVA in the UAE for two cancer indications, expanding its global footprint. Despite a recent share price pullback, the company is considered 45% undervalued, with a fair value of $13 compared to its last close of $7.17. The approval is expected to fuel future product revenue growth through the rapid global expansion of ANKTIVA into 33 countries.
The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval - Learn Why
ImmunityBio's ANKTIVA has received broad Marketing Authorization in the UAE, covering BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, marking its widest label yet across 34 countries. This approval is significant as it includes papillary-only bladder disease, mirroring ImmunityBio's ongoing efforts for FDA approval in the U.S. The development reinforces the global potential of ANKTIVA and could alter ImmunityBio's investment narrative, with analysts forecasting substantial revenue growth by 2029.
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease
ImmunityBio (IBRX) stock jumped nearly 8% after the UAE granted its cancer immunotherapy, Anktiva, its broadest approval yet for bladder and metastatic lung cancer. This approval covers a wider range of bladder cancer patients than currently allowed in the U.S. and follows founder Patrick Soon-Shiong's "July birthday news" tease. The company is seeking similar label expansion in the U.S. for papillary-only bladder cancer, with an FDA decision expected by January 6, 2027.
ImmunityBio receives UAE marketing authorizations for ANKTIVA across NMIBC and NSCLC
ImmunityBio (IBRX) has been granted marketing authorization in the UAE for its cancer drug ANKTIVA for two indications: BCG-unresponsive NMIBC and checkpoint-refractory metastatic NSCLC. This expands ANKTIVA's approvals to 34 countries, with the NMIBC approval being the first worldwide to cover CIS with/without papillary tumors and papillary-only disease, offering a bladder-preserving option. The authorization is based on strong clinical trial data for both indications, showing positive response rates and overall survival.
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug
ImmunityBio's ANKTIVA has received its broadest approval yet in the UAE for non-muscle invasive bladder cancer (NMIBC), covering the entire disease spectrum, and also for metastatic non-small cell lung cancer (NSCLC). This approval marks the fifth jurisdiction to greenlight ANKTIVA, expanding its global reach to 34 countries. Clinical trials demonstrated significant efficacy in both NMIBC and NSCLC, offering new treatment options for patients.
ImmunityBio Gains After UAE Approves ANKTIVA for Bladder and Lung Cancer Treatments
ImmunityBio (NASDAQ:IBRX) shares rose 7.5% after the United Arab Emirates approved its drug ANKTIVA for two cancer indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's international reach to 34 countries and is a significant milestone in the company's global commercialization strategy. The authorization was supported by positive data from the QUILT-3.032 and QUILT-3.055 clinical trials.
ImmunityBio stock jumps on UAE drug approval for ANKTIVA
ImmunityBio's shares rose 7.5% after the United Arab Emirates approved its drug ANKTIVA for two indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's global regulatory footprint to 34 countries and is the first worldwide approval for the full spectrum of BCG-unresponsive NMIBC. The authorization was based on successful clinical trials demonstrating high response rates and extended survival for patients.
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease
ImmunityBio (IBRX) shares rallied after the United Arab Emirates (UAE) granted Anktiva, the company's cancer immunotherapy, its broadest approval yet for bladder and metastatic lung cancer. This approval follows founder Patrick Soon-Shiong's "July birthday news" promise and positions the UAE as the first country to clear Anktiva for the full range of BCG-unresponsive non-muscle invasive bladder cancer, including papillary-only disease. ImmunityBio is also seeking to broaden Anktiva’s U.S. label to include papillary-only patients, with an FDA decision expected in January 2027.
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
ImmunityBio announced that the Emirates Drug Establishment (EDE) of the UAE has granted Marketing Authorization for its drug ANKTIVA® for two distinct indications: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). This authorization is significant as it represents the broadest approval for ANKTIVA to date, spanning the full spectrum of bladder cancer including papillary disease, and marks the fifth regulatory jurisdiction to approve the drug. The company highlighted clinical evidence supporting these approvals, showing high complete response rates and promising overall survival benefits in both NMIBC and NSCLC patients.
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
ImmunityBio announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA across two indications: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). This marks the fifth regulatory approval for ANKTIVA globally, making the UAE the first country to approve the drug for both CIS and papillary disease in NMIBC. The authorizations were supported by clinical trial data from the QUILT-3.032 and QUILT-3.06 studies, demonstrating promising efficacy and safety profiles for ANKTIVA in combination with BCG or immune checkpoint inhibitors.
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
ImmunityBio, Inc. has received marketing authorization from the Emirates Drug Establishment (EDE) in the UAE for its drug ANKTIVA® for two distinct indications: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). This approval is significant as it covers the broadest range to date for ANKTIVA in NMIBC, including both carcinoma in situ (CIS) and papillary disease, and expands the drug's global footprint to 34 countries. The authorizations are supported by clinical trials demonstrating ANKTIVA's efficacy in both bladder and lung cancer patients, with the NMIBC authorization being the first worldwide to span the full spectrum of BCG-unresponsive disease.
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat
ImmunityBio (IBRX) stock is currently experiencing a five-day losing streak, but retail traders are optimistic about upcoming earnings, hoping that "incredibly strong" Anktiva sales will reverse the trend. CEO Richard Adcock has indicated robust sales of Anktiva, with retail expectations for quarterly revenue ranging higher than consensus estimates. Beyond earnings, the company is focused on global expansion for Anktiva and pursuing regulatory approval for a broader patient group with the FDA.
Immunitybio Inc (IBRX) Institutional Confidence
Immunitybio Inc (IBRX) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 20.71%, marking a 32.91% increase quarter-over-quarter. Paul Tudor Jones is the largest institutional shareholder, holding 557.67K shares.
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by ImmunityBio, Inc. (NASDAQ:IBRX). The firm is encouraging investors who purchased ImmunityBio securities before January 19, 2026, and still hold them, to contact them to assist with the investigation. The investigation aims to determine if the company and its officers or directors engaged in misconduct.
ImmunityBio says it is ‘incredibly committed’ to Dunkirk
ImmunityBio is committed to its Dunkirk facility, once leased by the bankrupt Athenex, and aims to fulfill original promises of investment and job creation. The company is currently undergoing multi-million dollar renovations and addressing building deficiencies, with manufacturing expected to be operational by 2028. ImmunityBio recently received FDA approval for ANKTIVA, an immunotherapy drug for bladder cancer, and is actively hiring and building community partnerships to meet employment benchmarks.
